Abstract: A method of inhibiting hypercoagulation and/or thrombosis in a subject having or at risk of hypercoagulation or thrombosis includes administering to the subject an amount of a composition effective to inhibit MRP-8/14 and/or MRP-14 binding to platelet CD36 and inhibit hypercoagulation and/or thrombosis in the subject.

Abstract: A method of inhibiting hypercoagulation and/or thrombosis in a subject having or at risk of hypercoagulation or thrombosis includes administering to the subject an amount of a composition effective to inhibit MRP-8/14 and/or MRP-14 binding to platelet CD36 and inhibit hypercoagulation and/or thrombosis in the subject.

Abstract: A method of treating a subject having or at risk of a disease or disorder associated with aberrant leukocyte-platelet interactions includes administering to the subject a therapeutically effective amount of a monoclonal antibody or antigen binding portion thereof that specifically binds to at least one of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 to inhibit leukocyte arrest on adherent platelets in the subject.

Abstract: The invention provides methods of treating and preventing vascular diseases, by inhibiting cysteine proteases active at sites of vascular injury, particularly cathepsins K and S, by administering cystatin C or TGF-&bgr;1. Cystatin C is severely reduced in both atherosclerotic and aneurysmal aortic lesions. Also provided is a method of diagnosing a patient at risk of, or with, vascular injury by detecting low levels of circulating cystatin C.

Abstract: Compounds that specifically inhibit or reduce leukocyte adhesion or function are useful to enhance vascular healing and lessen restenosis of blood vessels after revascularization, via angioplasty or bypass surgery, of diseased coronary, peripheral and cerebral arteries, and lessen stenosis or restenosis of surgically-placed bypass grafts and transplanted organs. Examples of these compounds are those which block cell surface integrins or their ligands, for example, the leukocyte integrin Mac-1 (CD11b/CD18, &agr;M&bgr;2). As demonstrated by the examples, both superficial and deep injury was significantly reduced with treatment using an antibody to Mac-1 compared to both saline controls and IgG controls. After balloon angioplasty (superficial injury) neointimal area was reduced nearly 70%. The ratio of intimal:medial area, which is customarily used in balloon-injured experimental arteries to normalize for small normal variations in arterial size from one animal to another, was reduced over 75%.